Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial
Summary
reported receiving personal fees from Novo Nordisk, Becton Dickinson, Johnson & Johnson, and GT Metabolics outside the submitted work. Dr Kallio reported receiving personal fees from Mehiläinen outside the submitted work. No other disclosures were reported. 18. JAMA. 2026 Mar 23. doi: 10.1001/jama.2026.4179. Online ahead of print. Embracing Bayesian Methods in Clinical Trials: FDA's Long-Awaited Draft Guidance. Lee JJ(1), Harrell FE Jr(2), LaVange LM(3), Spiegelhalter DJ(4). Author information:
Content
# Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial
*Published: 2026 Mar 24*
reported receiving personal fees from Novo Nordisk, Becton Dickinson, Johnson & Johnson, and GT Metabolics outside the submitted work. Dr Kallio reported receiving personal fees from Mehiläinen outside the submitted work. No other disclosures were reported. 18. JAMA. 2026 Mar 23. doi: 10.1001/jama.2026.4179. Online ahead of print. Embracing Bayesian Methods in Clinical Trials: FDA's Long-Awaited Draft Guidance. Lee JJ(1), Harrell FE Jr(2), LaVange LM(3), Spiegelhalter DJ(4). Author information: (1)Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston. (2)Department of Biostatistics, Vanderbilt University, Nashville, Tennessee. (3)Department of Biostatistics, University of North Carolina at Chapel Hill. (4)Statistical Laboratory, Centre for Mathematical Sciences, Cambridge, United Kingdom. Plain Language Summary: This Perspective discusses the importance of the US Food and Drug Administration’s draft guidance on the use of bayesian methods in clinical trials because it underscores its commitment to modernizing clinical research. DOI: 10.1001/jama.2026.4179
DOI: 10.1001/jama.2025.25921